The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
Open Access
- 1 October 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (10) , 2023-2028
- https://doi.org/10.1093/annonc/mdq067
Abstract
Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy.Keywords
This publication has 37 references indexed in Scilit:
- Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trialsJournal of Clinical Oncology, 2007
- Sex Differences in Lung Cancer Survival: Do Tumors Behave Differently in Elderly Women?Journal of Clinical Oncology, 2007
- Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975Annals of Oncology, 2006
- Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594Journal of Thoracic Oncology, 2006
- A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)Annals of Oncology, 2006
- The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 yearsLung Cancer, 2005
- Lung Cancer Incidence Trends in Black and White Young Adults by Gender (United States)Cancer Causes & Control, 2004
- Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002The Annals of Thoracic Surgery, 2004
- Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer, 2003
- The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancerLung Cancer, 2002